The serotonin syndrome.
Claassen
Jurgen A H R
JA
Gelissen
Harry P M M
HP
D000368:Aged; D000732:Androstanols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003511:Cyclohexanols / Q000009:adverse effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use; D015742:Propofol / Q000627:therapeutic use; D012121:Respiration, Artificial; D000077123:Rocuronium; D020230:Serotonin Syndrome / Q000628:therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D014191:Tranylcypromine / Q000009:adverse effects; D000069470:Venlafaxine Hydrochloride
D000732:Androstanols; D003511:Cyclohexanols; D006993:Hypnotics and Sedatives; D008996:Monoamine Oxidase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D015742:Propofol; D000077123:Rocuronium; D017367:Selective Serotonin Reuptake Inhibitors; D014191:Tranylcypromine; D000069470:Venlafaxine Hydrochloride